These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 993584)

  • 21. Testing of hemolytic complement components in domestic animals.
    Barta O; Hubbert NL
    Am J Vet Res; 1978 Aug; 39(8):1303-8. PubMed ID: 697137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
    Kochi SK; Johnson RC; Dalmasso AP
    J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
    Hoover DL; Berger M; Hammer CH; Meltzer MS
    J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5b-9 complex of human complement.
    Bhakdi S; Bjerrum OJ; Bhakdi-Lehnen B; Tranum-Jensen J
    J Immunol; 1978 Dec; 121(6):2526-32. PubMed ID: 569173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI
    J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
    Hetland G; Bungum L
    APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reaction of partial identity between the C56-9 complex derived from target membranes and from inulin-activated serum.
    Bhakdi S; Bhakdi-Lehnen B; Ey P; Bjerrum OJ
    Monogr Allergy; 1977; 12():56-61. PubMed ID: 411027
    [No Abstract]   [Full Text] [Related]  

  • 28. The cytolytic attack mechanism of complement.
    Mayer MM
    Monogr Allergy; 1977; 12():1-12. PubMed ID: 335209
    [No Abstract]   [Full Text] [Related]  

  • 29. Complement component C7 is a plasminogen-binding protein.
    Reinartz J; Hänsch GM; Kramer MD
    J Immunol; 1995 Jan; 154(2):844-50. PubMed ID: 7814888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 32. Transmembrane channel-formation by five complement proteins.
    Müller-Eberhard HJ
    Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH; Shin ML; Abramovitz AS; Mayer MM
    J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of late complement components with membrane lesions.
    Rauterberg EW; Gebest HJ; Weissbach S
    Monogr Allergy; 1977; 12():62-5. PubMed ID: 917022
    [No Abstract]   [Full Text] [Related]  

  • 35. [Complement activation and biological activities].
    Inoue K
    Nihon Saikingaku Zasshi; 1976 Jul; 31(4):535-55. PubMed ID: 988219
    [No Abstract]   [Full Text] [Related]  

  • 36. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
    Brannen CL; Sodetz JM
    Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.